MedTrace Logo

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

NCT04405349 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-12-15

No results posted yet for this study

Summary

This phase IIa study is designed to evaluate the safety and efficacy of multiple dosing with VB10.16 immunotherapy in combination with atezolizumab in patients with advanced or recurrent non-resectable HPV16-positive cervical cancer, who failed or are not eligible for current standard of care.

Conditions

Interventions

BIOLOGICAL

VB10.16

Vaccination

BIOLOGICAL

Atezolizumab

Intravenously infusion

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Vaccibody AS

    collaborator INDUSTRY

  • Nykode Therapeutics ASA

    lead INDUSTRY

Principal Investigators

  • Siri Torhaug, MD · Nykode Therapeutics ASA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2023-11-24
Completion
2023-11-24

Countries

  • Belgium
  • Bulgaria
  • Czechia
  • Germany
  • Norway
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405349 on ClinicalTrials.gov